Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.
Latest from Joseph Haas
Semaglutide 7.2mg bests placebo for weight loss at 72 weeks, but with efficacy lower than seen with Novo Nordisk’s CagriSema or Lilly’s Zepbound.
Daily notebook from the J.P. Morgan Healthcare Conference: Insights from interviews with Astellas, Ultragenyx, Acadia and Tris Pharma; plus updates from Madrigal, Agios and Verve.
Plus deals involving Simcere/AbbVie, Daiichi Sankyo/Glycotope, Telix/ImaginAb, Harbour/Kelun/Windward, Insilico/Menarini, Samsung Bioepis/Teva, HealZen/J&J, Zai Lab/Vertex, Zai Lab/MediLink and Primrose/Serum Institute of India.
Plus deals involving Lantheus/Life Molecular Imaging, Teva/Klinge/Formycon, X4/Norgine, Biohaven/Merus, Lilly/Mediar and more.
With positive Phase IIb/III data for IGF-1r inhibitor linsitinib, privately held Sling plans to move into Phase III and compete in thyroid eye disease on convenience and safety.
Daily notebook from the J.P. Morgan Healthcare Conference: J&J's Duato talks about Intra-Cellular deal; GSK's Wood explains how IDRx fits its BD strategy; and Senator Burr says industry needs to look at the long term.